Inflectra becomes first FDA-approved biosimilar for inflammatory diseases

A biosimilar version of the anti–tumor necrosis factor–alpha agent Remicade has been approved by the Food and Drug Administration, making it the first biosimilar drug approved by the agency for inflammatory diseases and just the second biosimilar it has approved. The agency said in its April 5 <a...
Source: Skin and Allergy News - Category: Dermatology Source Type: news